Endo USA Inc., a Keenova Therapeutics Company
The primary purpose of this study is to assess the long-term safety of treatment and retreatment with KN3835 for flexible/semi-flexible HMT.
This extension study is for eligible participants who completed parent study KN3835-313 HMT. The study comprises 2 parts: * Part I: a double-blind Observation Period from Observational Day 1 to Observational Day 360, and * Part 2: an optional open-label Treatment/Retreatment Period from Observational Day 180 (Treatment/Retreatment Day 1) to Treatment/Retreatment Day 360 (End of Study).
Inclusion Criteria: * Were enrolled in and completed Study KN3835-313 (participants who completed the study are those that completed the Day 57/End of Study Visit, were assessed for safety, and received at least 1 dose of study intervention). * Has no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration or study required evaluations. * If female, be of non-childbearing potential or, if of childbearing potential, be non-pregnant, non-lactating and a…
Participants will receive KN3835 in Part 2 of the Study
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.